Literature DB >> 25190125

Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma.

Tatsuma Yamamoto1, Teiichi Sugiura, Takashi Mizuno, Yukiyasu Okamura, Takeshi Aramaki, Masahiro Endo, Katsuhiko Uesaka.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the clinical utility of preoperative 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic predictor of resectable pancreatic adenocarcinoma.
METHODS: A total of 128 patients with resected pancreatic adenocarcinoma who preoperatively underwent FDG-PET examinations were studied. The maximum standard uptake value (SUVmax) was calculated for each primary lesion. A receiver operating characteristics (ROC) curve was constructed to estimate the optimal cutoff value of the SUVmax. In order to determine which outcomes of interest were appropriately demonstrated, ROC curve analyses were conducted for six outcomes: 6-, 12-, and 24-month disease-free survival (DFS), and 6-, 12-, and 24-month overall survival (OS). A multivariate analysis was conducted to identify prognostic factors.
RESULTS: The ROC curves revealed that the SUVmax predicted the 6-month DFS most optimally (area under the curve 0.757), with a cutoff value of 6.0. Of the 69 patients with an SUVmax ≥ 6.0, 34 (49 %) developed recurrence within 6 months. In contrast, only 3 of 59 (5 %) patients with an SUVmax < 6.0 exhibited early recurrence (p < 0.001). The median OS time was 37 months in patients with an SUVmax < 6.0 and 18 months in patients with an SUVmax ≥ 6.0 (p < 0.001). The multivariate analysis revealed lymph node metastasis (hazard ratio [HR] 2.31; p = 0.001) and an SUVmax ≥ 6.0 (HR 2.05; p = 0.002) to be significantly correlated with a poor survival.
CONCLUSIONS: An SUVmax ≥ 6.0 was a significant predictor of early postoperative recurrence and subsequent poor survival following resection of pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25190125     DOI: 10.1245/s10434-014-4046-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  21 in total

1.  The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.

Authors:  Woohyun Jung; Jin-Young Jang; Mee Joo Kang; Ye Rim Chang; Yong Chan Shin; Jihoon Chang; Sun-Whe Kim
Journal:  HPB (Oxford)       Date:  2015-12-21       Impact factor: 3.647

2.  Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma.

Authors:  Yong-Il Kim; Yong Joong Kim; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-20       Impact factor: 9.236

Review 3.  Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals.

Authors:  Yu-Ping Xu; Min Yang
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

4.  Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).

Authors:  Ken-Ichi Okada; Manabu Kawai; Seiko Hirono; Fumiyoshi Kojima; Kensuke Tanioka; Masaki Terada; Motoki Miyazawa; Yuji Kitahata; Yoshifumi Iwahashi; Masaki Ueno; Shinya Hayami; Shin-Ichi Murata; Toshio Shimokawa; Hiroki Yamaue
Journal:  Langenbecks Arch Surg       Date:  2020-01-28       Impact factor: 3.445

5.  18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Kyohei Ariake; Fuyuhiko Motoi; Hideo Shimomura; Masamichi Mizuma; Shimpei Maeda; Chiaki Terao; Yasuko Tatewaki; Hideo Ohtsuka; Koji Fukase; Kunihiro Masuda; Hiroki Hayashi; Tatsuyuki Takadate; Takeshi Naitoh; Yasuyuki Taki; Michiaki Unno
Journal:  J Gastrointest Surg       Date:  2017-11-08       Impact factor: 3.452

6.  Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis.

Authors:  Marc A Attiyeh; Jayasree Chakraborty; Alexandre Doussot; Liana Langdon-Embry; Shiana Mainarich; Mithat Gönen; Vinod P Balachandran; Michael I D'Angelica; Ronald P DeMatteo; William R Jarnagin; T Peter Kingham; Peter J Allen; Amber L Simpson; Richard K Do
Journal:  Ann Surg Oncol       Date:  2018-01-29       Impact factor: 5.344

Review 7.  Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up.

Authors:  Rushika M Perera; Nabeel Bardeesy
Journal:  Cancer Discov       Date:  2015-11-03       Impact factor: 39.397

8.  Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.

Authors:  Hyung-Jun Im; Suthet Oo; Woohyun Jung; Jin-Young Jang; Sun-Whe Kim; Gi Jeong Cheon; Keon Wook Kang; June-Key Chung; E Edmund Kim; Dong Soo Lee
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

Review 9.  Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?

Authors:  Christopher Montemagno; Shamir Cassim; Nicolas De Leiris; Jérôme Durivault; Marc Faraggi; Gilles Pagès
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

10.  Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer.

Authors:  Chang Moo Kang; Sung Hwan Lee; Ho Kyoung Hwang; Mijin Yun; Woo Jung Lee
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.